JPM: How did Pfizer Up its COVID-19 Vaccine Capacity? ‘Out of the Box Manufacturing,’ CEO Says

Earlier this week, Pfizer partner BioNTech upped the pair’s 2021 COVID-19 output projection to 2 billion doses for 2021, up from a previous estimate of 1.3 billion. But how will the companies get there? By doing things “very differently and very out of the box in manufacturing,” CEO Albert Bourla explained Tuesday during a fireside chat at the J.P. Morgan Healthcare Conference, as reported by FierceHealthcare.

There are “so many initiatives we have put in place,” Mr. Bourla said, including changing the the way it works with partners on raw materials, reimagining its operational flow to improve capacity, designing new equipment—and working with manufacturers to get that new equipment delivered quickly—and more.

Read the full article.